Concord Drugs Limited announced significant changes to its Board structure following a meeting held on February 14, 2026. The company reconstituted its Board committees and disclosed the cessation of a director in compliance with SEBI regulations.

Board Committee Reconstitution

The Board of Directors approved the reconstitution of three key committees with immediate effect to ensure compliance with applicable statutory requirements. All three committees now share the same composition of independent directors.

Committee Composition

Director Cessation Details

The company also announced the cessation of Director Ramchandra Reddy Kommula from the Board. The cessation was disclosed under Regulation 30 of SEBI regulations.

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that the reconstitution aligns with statutory requirements and maintains proper corporate governance standards.

The restructuring ensures that all three critical Board committees maintain independent oversight with qualified non-executive independent directors serving across multiple committees to provide comprehensive governance coverage.

Concord Drugs Limited has announced the receipt of significant purchase orders totaling approximately ₹14.71 crores from various government entities during December 2025. The pharmaceutical company disclosed this development under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as the order value exceeds the materiality threshold prescribed under the company's policy.

Order Details and Awarding Entities

The purchase orders have been secured from multiple government healthcare organizations across different states. The key awarding entities include Tamil Nadu Medical Services Corporation Ltd. (TNMSC), which has placed orders under two categories - 6 purchase orders under regular procurement and 32 purchase orders under the Mudhalvar Marundhagam Scheme.

Contract Specifications and Timeline

The orders are exclusively for domestic supply of various pharmaceutical products to government healthcare institutions. All contracts are with domestic entities, reinforcing the company's strong position in the Indian pharmaceutical market.

Regulatory Compliance and Impact

Concord Drugs Limited has confirmed that the promoter, promoter group, or group companies have no interest in the entities that awarded these orders. The transactions do not fall within related party transactions, ensuring arm's length dealings. The company expects these orders to have a positive impact on its business and operations, given the substantial value and involvement of major government healthcare procurement agencies.

The disclosure was made in accordance with SEBI regulations and the Master Circular dated November 11, 2024, demonstrating the company's commitment to transparency and regulatory compliance in its business operations.